(BSTZ) BlackRock Science - Ratings and Ratios
Exchange: NYSE • Country: United States • Currency: USD • Type: Common Stock • ISIN: US09260K1016
BSTZ: Technology, Software, Healthcare, Internet, Semiconductors
BlackRock Science and Technology Trust II, trading under the ticker BSTZ on the NYSE, is a closed-ended equity mutual fund established in June 2019 by BlackRock, Inc. Managed by BlackRock Advisors, LLC, the fund is structured as a term trust, offering exposure to global public equity markets with a focus on the science and technology sectors. Its investment strategy centers on growth stocks across various market capitalizations, providing diversification in company sizes within these sectors.
With an assets under management (AUM) of $1.562 billion, BSTZ presents a substantial investment vehicle. The funds financial metrics include a price-to-earnings (P/E) ratio of 7.61, which is lower than many peers, suggesting potential undervaluation. The price-to-book (P/B) ratio of 0.90 indicates the fund is trading below its book value, appealing to value investors. These metrics highlight the funds attractive valuation profile.
As part of BlackRocks suite of investment products, BSTZ leverages the firms extensive expertise in asset management. The funds closed-ended structure offers a fixed number of shares, which can impact liquidity but may also provide stability. Domiciled in the United States, BSTZs tax implications for investors should be considered. Overall, it serves as a targeted investment option for those seeking exposure to science and technology sectors through a fund with a proven track record since its inception.
Additional Sources for BSTZ Stock
Tweets: X Stocktwits
Fund Manager Positions: Dataroma Stockcircle
BSTZ Stock Overview
Market Cap in USD | 1,187m |
Sector | Financial Services |
Industry | Asset Management |
GiC Sub-Industry | Asset Management & Custody Banks |
IPO / Inception | 2019-06-26 |
BSTZ Stock Ratings
Growth 5y | 20.9% |
Fundamental | - |
Dividend | 90.0% |
Rel. Strength | -9.81 |
Analysts | - |
Fair Price Momentum | 16.53 USD |
Fair Price DCF | 61.08 USD |
BSTZ Dividends
Dividend Yield 12m | 13.81% |
Yield on Cost 5y | 20.96% |
Annual Growth 5y | 10.15% |
Payout Consistency | 92.3% |
BSTZ Growth Ratios
Growth Correlation 3m | -80% |
Growth Correlation 12m | 73.2% |
Growth Correlation 5y | -18% |
CAGR 5y | 7.43% |
CAGR/Max DD 5y | 0.13 |
Sharpe Ratio 12m | 0.39 |
Alpha | 1.40 |
Beta | 1.287 |
Volatility | 29.90% |
Current Volume | 486.3k |
Average Volume 20d | 258.9k |
As of April 09, 2025, the stock is trading at USD 16.22 with a total of 486,323 shares traded.
Over the past week, the price has changed by -10.39%, over one month by -9.34%, over three months by -21.39% and over the past year by -3.65%.
Neither. Based on ValueRay Analyses, BlackRock Science is currently (April 2025) neither a good nor a bad stock to buy. It has a ValueRay Growth Rating of 20.93 and therefor a technical neutral rating according to historical growth.
Based on ValueRays Analyses, Dividends and Discounted-Cash-Flow, the Fair Value of BSTZ as of April 2025 is 16.53. This means that BSTZ is currently overvalued and has a potential downside of 1.91%.
BlackRock Science has no consensus analysts rating.
According to ValueRays Forecast Model, BSTZ BlackRock Science will be worth about 18.6 in April 2026. The stock is currently trading at 16.22. This means that the stock has a potential upside of +14.43%.
Issuer | Forecast | Upside |
---|---|---|
Wallstreet Target Price | - | - |
Analysts Target Price | - | - |
ValueRay Target Price | 18.6 | 14.4% |